Entity
OpenEvidence
OpenEvidence is a $15bn AI chatbot used by a reported two-thirds of US physicians for clinical decision support, notable for its ad-powered business model. Its rapid adoption has sparked debate over the influence of advertising on patient care.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
OpenEvidence is an AI-powered clinical decision support chatbot valued at $15bn, described as a "viral" AI start-up reshaping how American doctors treat patients (FT, October 21).
## Key Details
- The company's founder says two-thirds of US physicians use the ad-powered tool (FT, October 21).
- Valued at approximately $15 billion (FT, October 21).
- Its ad-supported business model has prompted a debate about patient care and the influence of advertising on clinical decision-making (FT, October 21).
## Why It Matters
OpenEvidence represents a significant case study in AI adoption within regulated healthcare settings, raising questions about conflicts of interest in ad-funded clinical tools, liability for AI-assisted medical decisions, and the broader trend of AI penetration into professional decision-making. Its scale of adoption (reportedly two-thirds of US physicians) suggests it could become a focal point for healthcare AI regulation.
## Open Questions
- How regulators (FDA, FTC) might respond to an ad-supported clinical tool.
- Whether the ad-powered model creates conflicts of interest affecting patient care.
- How the company's valuation and growth trajectory will evolve.